Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

October 22, 2025
PresentationRilogrotug

Cancer cachexia marker, Growth Differentiation Factor 15 (GDF-15), serum level mapping in real world samples from patients with pancreatic (PANC) or colorectal cancer (CRC)

July 17, 2025
PresentationTivozanib

Overview of Tivozanib (Tivo) Safety in Patients with Metastatic Renal Cell Carcinoma (mRCC)

May 30, 2025
PresentationFiclatuzumab

FIERCE-HN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab (HGF/c-MET MAb) in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

May 30, 2025
PresentationTivozanib

Efficacy of second line (2L) treatment with Tivozanib (Tivo) as monotherapy or with Nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the Phase 3 TiNivo-2 study

May 30, 2025
PresentationRilogrotug

A Phase 1b Dose Escalation Study of AV-380 (Anti-GDF15 Monoclonal Antibody) in Combination with Standard-of-Care Therapy in Cancer Patients with Cachexia

February 13, 2025
PresentationTivozanib

Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)

1 2 3 … 16

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.